Description
ROS1 rearrangements occur infrequently in lung ACA, however given the frequency of lung cancer in the population, ROS1-rearranged tumors represent a significant number of cancer patients. ROS1 gene rearrangements are reported in 1–2% of lung adenocarcinomas (ACA) and are associated with response to the multitargeted tyrosine kinase inhibitor, crizotinib. ROS IHC can be readily incorporated into the diagnostic surgical pathology workup of lung adenocarcinoma, with results confirmed by FISH as needed.
Additional information
| Catalog No. | RMPD108 Prediluted |
|---|---|
| Clone | EPMGHR2 |
| Isotype | IgG |
| Immunogen | Synthetic peptide within Human ROS1 aa 2050-2150. The exact sequence is proprietary. |
| Species | Rabbit |
| Cellular Localization | Diffuse Cytoplasmic |
| Positive Control Tissue | Lung carcinoma |
| Pretreatment | EDTA Buffer pH 8.0 |
| Incubation & Temperature | 60 min @ RT |
| Intended Use | IVD |
| Detection System | PolyVue Plus – Two Step Detection System or Montage PolyVue Plus Auto Detection System for Montage 360 System |
| Description/Type | Rabbit Monoclonal Antibody |
| Format | Purified immunoglobulin |
DATASHEETS & SDS
DATASHEETS & SDS
| Download Datasheet |
| Download SDS Sheet – OSHA |
REFERENCES
REFERENCES
- Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010 ;362: 2380–2388
- Rimkunas VM, Crosby KE, Li D, et al. Analysis of receptor tyrosine kinase ROS1- positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion. Clin Cancer Res. 2012;18:4449–4457.
Reviews (0)
Only logged in customers who have purchased this product may leave a review.
Reviews
There are no reviews yet.